Suzanne Bruhn, Phd

Biography

 Suzanne Bruhn is the president and CEO of Proclara. Already, she filled in as president and CEO of Promedior, a private, clinical-organize biotechnology organization spearheading the advancement of focused treatments to treat maladies including fibrosis. At Promedior, Bruhn administered the advancement of PRM-151, a recombinant human pentraxin-2 protein,, and arranged a concurrence with Bristol-Myers Squibb, giving them the selective ideal to secure Promedior and increase overall rights to its lead compound. Before Promedior, she filled in as senior VP, key arranging and program administration for Shire Human Genetic Therapies, Inc., where she assumed a key part in building up numerous protein therapeutics for vagrant maladies and in driving item methodology, portfolio and program administration, and worldwide administrative undertakings for the organization's uncommon ailment portfolio. She likewise worked at Cytotherapeutics, Inc. Bruhn presently serves on the Board of Directors of Aeglea BioTherapeutics (NASDAQ: AGLE) and Pliant Therapeutics, and once in the past served on the Board of Directors of Raptor Pharmaceuticals (NASDAQ: RPTP), preceding its 2016 obtaining by Horizon Pharma. She got a Bachelor of Science from Iowa State University, a doctorate in Chemistry from the Massachusetts Institute of Technology, and finished her postdoctoral association in the branch of human hereditary qualities at Harvard Medical School.

Research Interest

Neuro degenerative Diseases, Pheripherial Amyloidosis